Pulmonary Clinical Trials
| Condition | Description | Investigator | Contact Information |
| Cystic Fibrosis | CF Registry: Cystic Fibrosis Registry This study is an ongoing data collection effort sponsored by the Cystic Fibrosis Foundation, known as the Patient Registry. The goal of the Patient Registry is to collect data to better understand the illness and ultimately improve the care and survival of those with CF. The Patient Registry was established in 1966 as a means to monitor important trends in the CF population and to improve understanding, treatment and survival. |
Millard, Susan | Cynthia Gile Cynthia.Gile@spectrumhealth.org 616.391.6148 |
| Cystic Fibrosis | CFFC: A Long-Term Prospective Observational Safety Study of the Incidence of and Risk Factors for Fibrosing Colonopathy in US Patients with Cystic Fibrosis Treated with Pancreatic Enzyme Replacement Therapy: A Harmonized Protocol Across Sponsors (the "Study") A Long-Term Prospective Observational Safety Study of the Incidence of and Risk Factors for Fibrosing Colonopathy in US Patients with Cystic Fibrosis Treated with Pancreatic Enzyme Replacement Therapy: A Harmonized Protocol Across Sponsors For more information, click here. |
Millard, Susan | Cynthia Gile Cynthia.Gile@spectrumhealth.org 616.391.6148 |
| Cystic Fibrosis | Transition Study: Survey of Experiences with Transition to Adult Cystic Fibrosis Care This study is a research initiative to improve the process of transitioning from pediatric to adult cystic fibrosis care. |
McCaslin, Charles | Cynthia Gile Cynthia.Gile@spectrumhealth.org 616.391.6148 |
| Cystic Fibrosis | PROSPECT: A Two-Part Multicenter Prospective Longitudinal Study of CFTR-Dependent Disease Profiling in Cystic Fibrosis We are doing the PROSPECT Study to answer questions about Cystic Fibrosis (CF), a disease that affects the body’s ability to move salt and fluids in and out of the cells of the lungs, intestines, pancreas and sweat glands. CF is caused by changes (mutations) in a gene that produces a protein called the cystic fibrosis transmembrane conductance regulator (CFTR). Some of these mutations cause CFTR to lose all function while other mutations cause CFTR to lose some function. For more information, click here. |
Millard, Susan | Cynthia Gile Cynthia.Gile@spectrumhealth.org 616.391.6148 |
| Cystic Fibrosis | VX 661-109: A Phase 3, Randomized, Double-Blind, Ivacaftor-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation and a Second CFTR Allele With a Gating Defect That is Clinically Demonstrated to be Ivacaftor Responsive Genetic testing is testing of your DNA. DNA (or deoxyribonucleic acid) can be thought of as a ‘cook book’ that contains the recipe for your body. Your DNA may help us to understand why some people are more likely to get a certain disease, while others are not. Differences in DNA may also help explain why some drugs work and are safe in some people, but not in others. For more information, click here. |
Millard, Susan | Thomas Symington Thomas.Symington@spectrumhealth.org 616.391.9366 |
| Cystic Fibrosis | VX 661-110: A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis Who Have an F508del-CFTR Mutation This is an observational portion of the VX14-661-110 research study. This means that your CF treatment and medical care will not change because you are participating in this portion of the study. Your doctor will continue to make all decisions regarding your proper treatment and care. No part of this study is experimental. For more information, click here. |
Millard, Susan | Thomas Symington Thomas.Symington@spectrumhealth.org 616.391.9366 |
| Cystic Fibrosis | CELTAXSYS_CTX-4430_1_2015: EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult CF Patients We are trying to learn how your body processes the investigational new drug (CTX-4430) and measure the levels of Study Drug and other possible breakdown products of the Study Drug. For more information, click here. |
McCaslin, Charles | Cynthia Gile Cynthia.Gile@spectrumhealth.org 616.391.6148 |
| Cystic Fibrosis | Teach: Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With CF (TEACH) People with Cystic Fibrosis (CF) commonly get chronic infections in their lungs. One bacteria or germ called Pseudomonas aeruginosa (Pa) is particularly good at living in the CF lung. Pa is often treated with the antibiotics, azithromycin and inhaled tobramycin. There is some study data that suggests that azithromycin and inhaled tobramycin do not work as well when they are used together. We are investigating if this is true. For more information, click here. |
Millard, Susan | Cynthia Gile Cynthia.Gile@spectrumhealth.org 616.391.6148 |
| Cystic Fibrosis | VX 15-371-101: A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation In this study we want to learn more about the safety and effects of the inhaled combination of VX-371 with hypertonic saline (HS), in patients with CF who are being treated with lumacaftor/ivacaftor. The inhaled experimental medicine has been given to patients with CF before, but it is a new medicine and we are still learning about it. Lumacaftor given with ivacaftor has been approved by the FDA for patients 12 years and older with CF who have two copies of the F508del mutation. In all other CF patients with all other mutations and in all other countries, lumacaftor given with ivacaftor is considered experimental. For more information, click here. |
Millard, Susan | Thomas Symington Thomas.Symington@spectrumhealth.org 616.391.9366 |
| Pulmonary | BRAVE 1: Bronchial Sample Collection for a Novel Genomic Test The purpose of this study is to look at multiple lung tissue samples plus blood and cheek swab samples for external review to help create a less invasive formula that will diagnose interstitial lung disease (ILD) on bronchial biopsies with accuracy comparable or greater than high resolution CT. |
Schmidt, Shelly |
Melissa Boerman Melissa.Boerman@spectrumhealth.org 616.486.6082 |
| Pulmonary Fibrosis | Registry: The Pulmonary Fibrosis Patient Registry This study is a prospective chart review and questionnaires evaluating the progression of patients with a pulmonary fibrosis (PF) diagnosis who are cared for by Spectrum Health Medical Group (SHMG) Pulmonary. This registry will be used to create a database of information about this patient population. This information will be used to direct and coordinate patient care across the PFCC and also to research patient outcomes and predictors of outcomes. |
Schmidt, Shelly | Melisaa Boerman Melissa.Boerman@spectrumhealth.org 616.486.6082 |
You can also visit clinicaltrials.gov for opportunities internationally.